CN104957260B - Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation - Google Patents
Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation Download PDFInfo
- Publication number
- CN104957260B CN104957260B CN201510228239.9A CN201510228239A CN104957260B CN 104957260 B CN104957260 B CN 104957260B CN 201510228239 A CN201510228239 A CN 201510228239A CN 104957260 B CN104957260 B CN 104957260B
- Authority
- CN
- China
- Prior art keywords
- food
- composition
- group
- lactobacillus salivarius
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation the present invention provides a kind of.The composition includes Lactobacillus salivarius (Lactobacillus salivarius subsp.salicinius) and animal bifidobacteria (Bifidobacterium animalis subsp.lactis)；It is preferred that the Lactobacillus salivarius is the Lactobacillus salivarius of deposit number CCTCC No.M2011127, the animal bifidobacteria is the animal bifidobacteria of deposit number CGMCC No.5470.It may also include xylo-oligosaccharide and/or xylitol in the composition.The probiotic food composition of the present invention can add in various healthy food and health food are such as acidified milk, milk tablet, can be used for being effectively relieved bottleneck throat inflammation especially chronic pharyngitis.
Description
It is on 03 07th, 2014 that the present invention, which is application No. is the 201410083030.3, applying date, entitled " is had
The divisional application of the probiotic food composition and food of alleviation bottleneck throat inflammation effect ".
Technical field
Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation, tool present invention is primarily about a kind of
Body refers to a kind of probiotic food composition comprising Lactobacillus salivarius, animal bifidobacteria, and bottleneck throat inflammation can be effectively relieved
Especially chronic pharyngitis, the composition can add in various healthy food and health food are such as acidified milk, milk tablet.
Background technology
Chronic pharyngitis (sphagitis) is a kind of relatively conventional disease, is under bottleneck throat mucous membrane, mucous membrane and lymphoid tissue
Diffusivity inflammation is often a part for upper respiratory tract chronic inflammation, and the general course of disease is tediously long, obstinate refractory, life to patient and
Work, which all causes, to be seriously affected.The illness reason of chronic pharyngitis mainly has：1, acpuei pharyngitis recurrent exerbation switchs to chronic.2, suffer from
There are various rhinopathys, long-term mouth breathing and postnasal drip, often stimulate pharyngeal, or is influenced by chronic tonsillitis, saprodontia etc..
3, long-term excessive drinking and smoking, or stimulated by dust, pernicious gas, it can all cause this disease.4, various chronic diseases, as anaemia, constipation,
Tired courageous and upright change caused by angiocardiopathy, lower respiratory tract chronic inflammation etc., all can secondary chronic pharyngitis.5, sphagitis is induced
The cause of disease also has systemic factor, lives for a long time irregular, and fatigue, stress make passive protective physical fitness decline, and bacterium and virus are easy
Repeated infection, the people of allergic constitution is easy to catch cold to the change tetchiness of external environment, weather, causes pharyngitis.
It is compound Chinese medicinal preparation class that the drug ingredient for the treatment of chronic pharyngitis, which is mainly concentrated, at present, and ingredient is also concentrated mainly on gold
The traditional Chinese medicine ingredients such as honeysuckle flower, green tea, but drug effect is significantly rare, while drug therapy is used for a long time and deposits many drawbacks.
In recent years, foreign countries have correlative study to show that probiotics has the effect of alleviation and treatment chronic pharyngitis：John in 2003
R.Tagg etc. thinks that Streptococcus salivarius K12 can effectively prevent the sphagitis caused by streptococcus；2007
Year H.-P.Horz etc. more confirms that this plant of bacterium can effectively colonize on oral mucosa Fine born of the same parents；In addition to this, for herpetic mouth
In the scorching virus of chamber, probiotics also has its validity, and it is antiviral that Tanja Botic in 2007 et al. think that probiotics can secrete
Substance reduces the infection rate of herpes stomatitis virus and the viral content in oral cavity Inner；It is not unique, but has its counterpart in 2007,
Martin Ivec etc. propose that probiotics, in the reciprocation of mucous membrane of mouth, it is antiviral can to increase macrophage with macrophage
Ability fight herpes stomatitis virus.
However, the research that probiotics is used for alleviating and treating bottleneck throat inflammation is merely resting on experimental study level at present,
There is no relevant clinical product both at home and abroad.
Invention content
Have effects that alleviate the probiotic food composition of bottleneck throat inflammation it is an object of the present invention to provide a kind of, with
Food is made, for consumer's instant edible, while having effects that alleviate bottleneck throat inflammation.
Another object of the present invention is to provide the probiotic food compositions to prepare with alleviation bottleneck throat inflammation
Application in the food of disease effect.
Have effects that alleviate the food of bottleneck throat inflammation, especially a kind of milk another object of the present invention is to provide a kind of
Piece.
On the one hand, have effects that alleviate the probiotic food composition of bottleneck throat inflammation, the group the present invention provides a kind of
It includes Lactobacillus salivarius and animal bifidobacteria to close object.
Specific embodiment according to the present invention, in composition of the invention, the Lactobacillus salivarius is Lactobacillus salivarius
Salicin subspecies (Lactobacillus salivarius subsp.salicinius), animal bifidobacteria are animal bifid
Bacillus breast subspecies (Bifidobacterium animalis subsp.lactis).
More specifically, in composition of the invention, the Lactobacillus salivarius is preferably deposit number CCTCC
The Lactobacillus salivarius of No.M2011127, the animal bifidobacteria are preferably the animal bifid of deposit number CGMCC No.5470
Bacillus.
Deposit number is that the Lactobacillus salivarius of CCTCC No.M2011127 is also known as Lactobacillus salivarius
Subsp.salicinius AP-32 have been preserved in China typical culture collection center (CCTCC), preservation address：It is Chinese military
Wuhan University of Chinese city Life Science College, Classification And Nomenclature：Lactobacillus salivarius salicin subspecies Laclobacillus
Salivarius subsp.salicinius, deposit number：CCTCC No.2011127, preservation date：On April 10th, 2011.
It is Lactobacillus salivarius CCTCC No.M2011127 that the bacterium is also known as in the present invention.It is known in the art, it see, for example,
CN102835666A, Lactobacillus salivarius CCTCC No.M2011127 have the ability of anti-stomach Helicobacter pylori, including inhibit stomach
The activity of helicobacter pylori, for caused by stomach Helicobacter pylori antibiosis extract for treating side effect (such as diarrhea etc.) and
The uncomfortable symptom of stomach (such as gaseous distention, hydrochloric acid in gastric juice adverse current etc.) has the functional activity slowed down.
The deposit number is that the animal bifidobacteria of CGMCC No.5470 is also known as Bifidobacterium animalis
Subsp.lactis V9 have been preserved in China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC), protect
Hide address：BeiChen West Road, Chaoyang District, BeiJing City I institutes 3, Classification And Nomenclature：Bifidobacterium animalis subspecies
Bifidobacterium animalis subsp.lactis, deposit number：CGMCC No.5470, preservation date：2011
November 18.It is animal bifidobacteria CGMCC No.5470 that the bacterium is also known as in the present invention.It is known in the art, it see, for example,
CN102851223A, animal bifidobacteria CGMCC No.5470 can dramatically increase active isoflavan and contain during soya-bean milk fermentation
Amount, makes inactive isoflavones be converted into functional activity isoflavones.In addition, Bifidobacterium animalis
Subsp.lactis V9 bacterium powders can be effectively improved intestinal flora, have to a certain degree for constipation, acute diarrhea, chronic diarrhea
Therapeutic effect (referring to " and with prebiotic function Bifidobacterium animalis subsp.lactis V9 safety
Property assessment, physiological function and its full-length genome study ", Chen Xia,《Agricultural University of the Inner Mongol》2010).
Inventor surprisingly has found under study for action, by Lactobacillus salivarius CCTCC No.M2011127 and animal bifid
Bacillus CGMCC No.5470 are combined, and resulting composition has effects that significantly to alleviate bottleneck throat inflammation, especially both benefits
The composition of raw bacterium is for the pharynx foreign body sensation for improving pharyngo-laryngitis chronica patient, brush teeth nausea, pharyngeal mucosa hyperemia, myxedema etc.
Synergistic effect is played in terms of symptom.The composition including Lactobacillus salivarius and animal bifidobacteria of the present invention has for one kind
Alleviate the probiotic food composition of bottleneck throat inflammation effect.
Specific embodiment according to the present invention, the probiotic food group with alleviation bottleneck throat inflammation of the invention
It closes in object, the ratio of the viable count of the Lactobacillus salivarius and animal bifidobacteria is 1:0.01~1, preferably 1:0.08~
0.12, most preferably from about 1:0.1.
Specific embodiment according to the present invention, the probiotic food group with alleviation bottleneck throat inflammation of the invention
Object is closed, can also further comprise xylo-oligosaccharide and/or xylitol.It is highly preferred that in the composition, xylo-oligosaccharide and animal bifid
The ratio of bacillus is 100g~150g xylo-oligosaccharides：5×1010CFU~5 × 1011CFU animal bifidobacterias.Xylitol and animal
The ratio of Bifidobacterium is 100g~150g xylitols：5×1010CFU~5 × 1011CFU animal bifidobacterias.
On the other hand, the present invention also provides the compositions comprising Lactobacillus salivarius and animal bifidobacteria to make
It is standby to have effects that alleviate the application in the food of bottleneck throat inflammation.
On the other hand, have effects that alleviate the food of bottleneck throat inflammation, the raw material of the food the present invention also provides a kind of
Composition includes the composition of the present invention for including Lactobacillus salivarius and animal bifidobacteria.
Specific embodiment according to the present invention, in composition of the invention, Lactobacillus salivarius CCTCC No.M2011127
The animal bifidobacteria CGMCC No.5470 of pharynx foreign body sensation, brush teeth nausea, pharyngeal mucosa with to(for) improvement pharyngo-laryngitis chronica patient
Synergistic effect is played in terms of the symptoms such as hyperemia, myxedema, has effects that significantly to alleviate bottleneck throat inflammation, the composition
It can be added in various probiotic foods, the food for having effects that alleviate bottleneck throat inflammation is prepared.Preferably, of the invention
Have effects that alleviate bottleneck throat inflammation food in, Lactobacillus salivarius viable count be 5 × 1011CFU/kg~5 × 1012CFU/
Kg, animal bifidobacteria viable count are 5 × 1010CFU/kg~5 × 1011CFU/kg。
Specific embodiment according to the present invention, the food with alleviation bottleneck throat inflammation of the invention, Ke Yiwei
Freeze-dried powder, capsule, granule, the solid-state food for swallowing the forms such as tablet or lozenge, or may be oral solution or beverage etc.
The food liquid of form.
It is provided by the invention to have effects that alleviate bottleneck throat inflammation in the preferred embodiment of the present invention
Food is the milk tablet for sucking sheet form.
The food alleviate with bottleneck throat inflammation of the present invention is the milk tablet for sucking sheet form, can be with existing
Milk tablet raw material composition is carrier, and that adds the present invention has effects that the probiotic food composition of alleviation bottleneck throat inflammation, and makes
A kind of standby obtained activity including Lactobacillus salivarius CCTCC No.M2011127 and animal bifidobacteria CGMCC No.5470
Probiotic milk tablets.Specifically, in addition to the probiotic food composition with alleviation bottleneck throat inflammation of the present invention,
Further include milk tablet base-material in the raw material composition of the milk tablet of the present invention, the milk tablet base-material includes milk powder, is also optionally included with
Carbohydrate, food flavor and food enrichment etc. can add one or more as auxiliary in the food additives in milk tablet
Material.Wherein, the milk powder can be whole milk powder, low fat milk powder or skimmed milk power, and the carbohydrate can be white granulated sugar or one
Common substance in milk tablet field can be used in a little sweeteners, other auxiliary materials such as the food flavor and food enrichment,
Each raw material of milk tablet base-material, which can refer to existing milk tablet, carries out dispensing (has effects that the prebiotic of alleviation bottleneck throat inflammation as the present invention
It can take the circumstances into consideration to reduce carbohydrate dosage when in bacterium food compositions comprising xylo-oligosaccharide, xylitol, in the composition of milk tablet base-material).
The present invention's has effects that alleviate in the milk tablet of bottleneck throat inflammation, and Lactobacillus salivarius viable count is 5 × 1011CFU/kg
~5 × 1012CFU/kg, animal bifidobacteria viable count are 5 × 1010CFU/kg~5 × 1011CFU/kg。
It on the other hand, should the present invention also provides the preparation method of the above-mentioned milk tablet alleviate with bottleneck throat inflammation
Method includes：
Milk tablet base-material is crossed 12 mesh to sieve to obtain milk tablet base stock powder, by Lactobacillus salivarius bacterium powder, animal bifidobacteria bacterium powder, low
It is added in milk tablet base stock powder after xylan, xylitol premix, dry-mixed 20~30 minutes, it is 50~60,000 Ns to adjust tablet press machine pressure
Milk tablet is prepared in tabletting afterwards.
Preferably, for the present invention during preparing milk tablet, control milk tablet base stock powder water activity is 0.15~0.2.
Inventor has found that the pressure of milk tablet of the invention in tableting processes survives to milk tablet finished product probiotics under study for action
Rate has certain influence, and when tableting pressure is 50~60,000 Ns, the survival rate of probiotics is about 58~75% in gained milk tablet
Left and right is (with probiotics additive amount for 9 × 108For CFU/g, tableting pressure are 60,000 Ns, after testing, viable count in gained milk tablet
It is 5.38 × 108CFU/g, survival rate 59.7%).Tableting pressure is excessive, and the survival rate of probiotics reduces in milk tablet, with prebiotic
Bacterium additive amount is 9 × 108CFU/g, tableting pressure be 65,000 Ns for, after testing, in gained milk tablet viable count be 9.88 ×
107CFU/g, survival rate only 10.9%.Tableting pressure is too small, and milk tablet molding effect is poor.
The packaged forms such as PVDC films, aluminium foil film, aluminium foil bag can be used in the milk tablet of the present invention, and milk tablet is in transport and sales process
In must assure that cold chain configure (2-6 DEG C).
In the preparation method of the milk tablet of aforementioned present invention, the operation that does not refer in detail can routinely milk tablet technology of preparing into
Row.
The present invention proved by human clinical trial, it is of the invention comprising Lactobacillus salivarius CCTCC No.M2011127 with
The composite active probiotics milk powder candy of animal bifidobacteria CGMCC No.5470 has very well patients with chronic pharyngitis bottleneck throat inflammation shape
Mitigation, volunteer's chronic pharyngitis sign of edible milk tablet obtained good control, it is compound prebiotic to have affirmed fully this
Bacterium milk tablet is in the effect for alleviating bottleneck throat aspect of inflammation.
Description of the drawings
Fig. 1 is the production technological process of the compound probiotic milk tablet of the present invention.
Fig. 2 is that foreign body sensation remission effect comparison diagram is swallowed in the embodiment of the present invention 2.
Fig. 3 is nauseous remission effect comparison diagram of brushing teeth in the embodiment of the present invention 2.
Fig. 4 is 2 mesopharynx mucous hyperemia remission effect comparison diagram of the embodiment of the present invention.
Fig. 5 is 2 mesopharynx lymph follicle remission effect comparison diagram of the embodiment of the present invention.
Fig. 6 is that foreign body sensation remission effect comparison diagram is swallowed in the embodiment of the present invention 3.
Fig. 7 is nauseous remission effect comparison diagram of brushing teeth in the embodiment of the present invention 3.
Fig. 8 is 3 mesopharynx mucous hyperemia remission effect comparison diagram of the embodiment of the present invention.
Fig. 9 is 3 mesopharynx lymph follicle remission effect comparison diagram of the embodiment of the present invention.
Specific implementation mode
In order to which technical characteristic, purpose and the advantageous effect to the present invention are more clearly understood, in conjunction with specific example
Technical scheme of the present invention is carried out described further below, it should be understood that these examples are merely to illustrate the present invention rather than limitation
The scope of the present invention.
Embodiment 1, milk tablet of compound probiotic and preparation method thereof
With reference to this field routine milk tablet preparation method prepare the present embodiment contain Lactobacillus salivarius CCTCC
The milk tablet of No.M2011127, animal bifidobacteria CGMCC No.5470, xylo-oligosaccharide, xylitol.Briefly, the method is joined
Technological process as shown in Figure 1 mainly includes the following steps that：
1) dispensing：Each raw material is weighed according to components by weight percent, is uniformly mixed；In the present embodiment, with every kilogram of milk tablet
Weight meter, each raw material proportioning is：Lactobacillus salivarius bacterium powder 9 × 1011CFU, animal bifidobacteria 9 × 1010CFU, xylo-oligosaccharide
125g, xylitol 125g, surplus are milk powder base stock powder (whole milk powder), base stock powder water activity 0.18；
2) sieving (crossing 12 mesh sieve)；
3) probiotic powder and prebiotics premix；
4) dry-mixed 20~30 minutes；
5) tabletting：Adjusting tablet press machine pressure is 55,000 Niu Jinhang tablettings；A diameter of 15~the 25mm of gained milk tablet, piece weigh about 2
Gram；
6) it packs：Milk tablet is made in PVDC films, aluminium foil film or aluminium foil bag.It is transporting and is ensuring cold chain configuration in sales process
(2-6℃)。
After testing, in milk tablet obtained by the present embodiment, Lactobacillus salivarius survival number about 5.88 × 1011CFU/kg, animal bifid
Bacillus 5.89 × 1010CFU/kg。
Embodiment 2, probiotic milk tablets alleviate bottleneck throat inflammation clinical research
It chooses 25 years old to 55 years old and suffers from slight pharyngitis or pharyngeal discomfort sex volunteer 240.It is randomly divided into 4
Group, every group of 60 people：
Group 0 --- blank control group (milk powder base-material milk tablet)；
Group 1 --- Lactobacillus salivarius milk tablet group；
Group 2 --- the compound probiotic milk tablet group (Lactobacillus salivarius of embodiment 1：Animal bifidobacteria is about 1:0.1)；
Group 3 --- animal bifidobacteria milk tablet group.
Each group milk tablet is prepared that (milk tablet of group 0 is prepared into milk powder base-material direct tablet compressing with reference to the method for embodiment 1
It arrives, is not added with probiotics and prebiotics；Compared with Example 1, difference is that only addition saliva is newborn respectively to the milk tablet of group 1 and group 3
Bacillus and animal bifidobacteria, remaining dispensing is with embodiment 1).
Test-meal method and observation index
Group 0 takes the milk tablet prepared with milk powder base-material tabletting；4 grams of milk tablet is taken in a manner of mouth containing daily, each 2 grams sooner or later
(a piece of), right place distribution.
Group 1 takes Lactobacillus salivarius milk tablet, contains Lactobacillus salivarius viable count of the present invention in every gram of milk tablet finished product
About 6.50 × 108CFU takes 4 grams of milk tablet in a manner of mouth containing daily, sooner or later each 2 grams (a piece of), right place distribution.
Group 2 takes the compound probiotic milk tablet of the preparation of embodiment 1, contains saliva breast bar of the present invention in every gram of milk tablet
Bacterium viable count is 5.88 × 108CFU, animal bifidobacteria viable count are 5.89 × 107CFU.Milk tablet is taken in a manner of mouth containing daily
4 grams, sooner or later each 2 grams (a piece of), right place distribution.
Group 3 takes animal bifid milk tablet, is containing animal bifidobacteria viable count of the present invention in every gram of milk tablet
6.61×108CFU takes 4 grams of milk tablet in a manner of mouth containing daily, sooner or later each 2 grams (a piece of), right place distribution.
Each group volunteer maintains diet during test-meal.
Observation index is symptom index 2, respectively swallows foreign body sensation and nausea of brushing teeth, wherein pharynx foreign body sensation is according to serious journey
Degree is divided into asymptomatic (0 point), slight (2 points), moderate (4 points), severe (6 points), and nausea of brushing teeth is denoted as asymptomatic (0 point), has disease
Shape (2 points).
The hyperemia of sign Index 2, respectively pharyngeal mucosa, myxedema, each symptom are divided into according to severity without (0
Point), slight (2 points), moderate (4 points), severe (6 points).
Efficacy assessment standard
Clinical recovery：Symptom/sign disappears.
It is effective：Symptom/sign improves 1 grade.
In vain：Symptom/sign is without change.
Data statistics
Each group symptom, sign severity distribution proportion are analyzed with rank sum test, improvement rate comparison chi-square criterion between group, inspection
Test level 0.01.Enumeration data is usedIt indicates, the analysis of test-meal symptom integral is examined with t-, inspection level 0.01.With
SPSS16.0 is analyzed.
Result judgement
Pharyngeal symptoms and therapeutic effect
The analysis of severity homogeneity and effective percentage are carried out to 2 the pharynx foreign body sensation of four groups of volunteers, nausea of brushing teeth symptoms
Comparative analysis.As a result referring to Fig. 2 and Fig. 3.
Fig. 2 is that four groups of volunteers swallow the comparison of foreign body sensation remission effect.The result shows that the effect of group 1, group 2, is significantly better than
Group 0 and group 3, group 2 is better than group 1, and difference is not notable between group 0 and group 3.
Fig. 3 is that four groups of volunteers brush teeth the comparison of nauseous remission effect.The result shows that the effect of group 1, group 2, is significantly better than
Group 0 and group 3, group 2 is better than group 1, and difference is not notable between group 0 and group 3.
Pharyngeal sign efficacy analysis
To 2 signs of pharyngeal mucosa hyperemia and pharyngeal lymph follicle of four groups of volunteers carry out into group when severity be distributed
Analysis and efficient comparative analysis.As a result referring to Fig. 4 and Fig. 5.
Fig. 4 is that four groups of volunteer's pharyngeal mucosa hyperemia remission effects compare.The result shows that the effect of group 1, group 2, is notable
Better than group 0 and group 3, group 2 is better than group 1, and difference is not notable between group 0 and group 3.
Fig. 5 is the pharyngeal lymph follicle remission effect comparison of two groups of volunteers.The result shows that the effect of group 1, group 2, is notable
Better than group 0 and group 3, difference is not notable between group 1, group 2, and difference is not notable between group 0 and group 3.
Embodiment 3, different proportion compound probiotic milk tablet alleviate bottleneck throat inflammation clinical research
It chooses 25 years old to 55 years old and suffers from slight pharyngitis or pharyngeal discomfort sex volunteer 240.It is randomly divided into 4
Group：
Group 0 --- blank control group (with the milk powder base-material milk tablet in embodiment 2)；
Group 1 --- compound probiotic milk tablet A group (Lactobacillus salivarius：Animal bifidobacteria is about 1:1)；
Group 2 --- the compound probiotic milk tablet B group (Lactobacillus salivarius of embodiment 1：Animal bifidobacteria is about 1:0.1)；
Group 3 --- compound probiotic milk tablet C group (Lactobacillus salivarius：Animal bifidobacteria is about 1:0.01).
Each group milk tablet is prepared that (milk tablet of group 0 is prepared into milk powder base-material direct tablet compressing with reference to the method for embodiment 1
It arrives, is not added with probiotics and prebiotics；Group 1 with group 3 milk tablet compared with Example 1, difference be add Lactobacillus salivarius with
The ratio of animal bifidobacteria is different, remaining dispensing is with embodiment 1).
Test-meal method and observation index
Group 0 takes the milk tablet (each 2 grams sooner or later, right place distribution) that 4g is prepared with milk powder base-material tabletting daily.
Group 1 takes 4g compound probiotic milk tablets A (each 2 grams sooner or later, right place distribution) daily, contains this in every gram of milk tablet
The invention Lactobacillus salivarius viable count is 5.81 × 108CFU, animal bifidobacteria viable count are 5.76 × 108CFU。
Group 2 takes 4g compound probiotic milk tablets B (each 2 grams sooner or later, right place distribution) daily, contains this in every gram of milk tablet
The invention Lactobacillus salivarius viable count is 5.88 × 108CFU, animal bifidobacteria viable count are 5.89 × 107CFU。
Group 3 takes 4g compound probiotic milk tablets C (each 2 grams sooner or later, right place distribution) daily, contains this in every gram of milk tablet
The invention Lactobacillus salivarius viable count is 5.00 × 109CFU, animal bifidobacteria viable count are 5.02 × 107CFU。
Each group volunteer maintains diet during test-meal.
Observation index
With embodiment 2.
Efficacy assessment standard and data statistics
With embodiment 2.
Result judgement
Pharyngeal symptoms and therapeutic effect
The analysis of severity homogeneity and effective percentage are carried out to 2 the pharynx foreign body sensation of four groups of volunteers, nausea of brushing teeth symptoms
Comparative analysis.As a result referring to Fig. 6 and Fig. 7.
Fig. 6 is that four groups of volunteers swallow the comparison of foreign body sensation remission effect.The result shows that the effect of group 1, group 2, group 3, is notable
Better than group 0, difference is not notable between group 1, group 2 and group 3.
Fig. 7 is that four groups of volunteers brush teeth the comparison of nauseous remission effect.The result shows that the effect of group 1, group 2, group 3, is notable
Better than group 0, difference is not notable between group 1, group 2 and group 3.
Pharyngeal sign efficacy analysis
To 2 signs of pharyngeal mucosa hyperemia and pharyngeal lymph follicle of two groups of volunteers carry out into group when severity be distributed
Analysis and efficient comparative analysis.As a result referring to Fig. 8 and Fig. 9.
Fig. 8 is that four groups of volunteer's pharyngeal mucosa hyperemia remission effects compare.The result shows that the effect of group 1, group 2, group 3, is equal
It is significantly better than group 0, difference is not notable between group 1, group 2 and group 3.
Fig. 9 is the pharyngeal lymph follicle remission effect comparison of four groups of volunteers.The result shows that the effect of group 1, group 2, group 3, is equal
It is significantly better than group 0, difference is not notable between group 1, group 2 and group 3.
It is verified through above-mentioned human clinical trial, is had using the compound probiotic milk tablet of the present invention and alleviate pharynx foreign body sensation, brush
The effect of malaise symptoms such as tooth nausea, eats the hyperemia of volunteer's pharyngeal mucosa and the filter of pharyngeal lymph of above-mentioned compound probiotic milk tablet
2 signs of bubble are obtained for good control, have affirmed fully the food compositions in the effect for alleviating bottleneck throat aspect of inflammation.
Above-mentioned clinical effectiveness is shown, is eaten in alleviation bottleneck throat aspect of inflammation and is contained a effective amount of Lactobacillus salivarius and animal
Bifidobacterium milk tablet clearing effect is better than single a effective amount of Lactobacillus salivarius milk tablet of addition；Single addition animal bifidobacteria
Milk tablet does not have the effect for alleviating bottleneck throat inflammation；Different proportion compound probiotic is alleviating bottleneck throat aspect of inflammation effect phase
Closely.In view of the production cost of probiotic milk tablets, recommend the 2nd group of (saliva of compound probiotic milk tablet in selection example 3 in production
Lactobacillus：Animal bifidobacteria=1:0.1) formula.
Claims (10)
1. a kind of have effects that alleviate the probiotic food composition of bottleneck throat inflammation, the composition is by Lactobacillus salivarius and animal
Bifidobacterium is as the active principle composition for alleviating bottleneck throat inflammation；
The Lactobacillus salivarius is the Lactobacillus salivarius of deposit number CCTCC No.M2011127, and the animal bifidobacteria is
The animal bifidobacteria of deposit number CGMCC No.5470；The ratio of the viable count of the Lactobacillus salivarius and animal bifidobacteria
Example is 1:0.01~1.
2. composition according to claim 1, wherein the ratio of the viable count of the Lactobacillus salivarius and animal bifidobacteria
Example is 1:0.08~0.12.
3. a kind of have effects that alleviate the probiotic food composition of bottleneck throat inflammation, the composition is by according to claims 1 or 2
The composition and xylo-oligosaccharide and/or xylitol composition.
4. composition according to claim 3, in the composition, the ratio of xylo-oligosaccharide and animal bifidobacteria is 100g
~150g xylo-oligosaccharides:5×1010CFU~5 × 1011The ratio of CFU animal bifidobacterias, xylitol and animal bifidobacteria is
100g~150g xylitols:5×1010CFU~5 × 1011CFU animal bifidobacterias.
5. Claims 1 to 4 any one of them composition is preparing answering in having effects that the food for alleviating bottleneck throat inflammation
With.
6. a kind of have effects that alleviate the food of bottleneck throat inflammation, the raw material composition of the food includes that Claims 1 to 4 is any
Composition described in, wherein Lactobacillus salivarius and animal bifidobacteria are as the active principle for alleviating bottleneck throat inflammation.
7. food according to claim 6, in the food, Lactobacillus salivarius viable count is 5 × 1011CFU/kg~5 ×
1012CFU/kg, animal bifidobacteria viable count are 5 × 1010CFU/kg~5 × 1011CFU/kg。
8. the food described according to claim 6 or 7, which is freeze-dried powder, capsule, granule, swallows tablet or lozenge shape
The solid-state food of formula, or be oral solution or the food liquid of drink form.
9. the food described according to claim 6 or 7, which is the milk tablet containing sheet form.
Further include milk tablet base-material in the raw material composition of the food 10. food according to claim 9, the milk tablet base-material
Also include selectively one or more in the food additives that can be added in milk tablet including milk powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510228239.9A CN104957260B (en) | 2014-03-07 | 2014-03-07 | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410083030.3A CN103798392B (en) | 2014-03-07 | 2014-03-07 | There is the probiotic food composition and food of alleviating bottleneck throat inflammation effect |
| CN201510228239.9A CN104957260B (en) | 2014-03-07 | 2014-03-07 | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410083030.3A Division CN103798392B (en) | 2014-03-07 | 2014-03-07 | There is the probiotic food composition and food of alleviating bottleneck throat inflammation effect |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104957260A CN104957260A (en) | 2015-10-07 |
| CN104957260B true CN104957260B (en) | 2018-07-24 |
Family
ID=50696167
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510228239.9A Active CN104957260B (en) | 2014-03-07 | 2014-03-07 | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation |
| CN201410083030.3A Active CN103798392B (en) | 2014-03-07 | 2014-03-07 | There is the probiotic food composition and food of alleviating bottleneck throat inflammation effect |
| CN201510227769.1A Active CN104886255B (en) | 2014-03-07 | 2014-03-07 | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410083030.3A Active CN103798392B (en) | 2014-03-07 | 2014-03-07 | There is the probiotic food composition and food of alleviating bottleneck throat inflammation effect |
| CN201510227769.1A Active CN104886255B (en) | 2014-03-07 | 2014-03-07 | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN104957260B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201611486D0 (en) * | 2016-06-30 | 2016-08-17 | Promovita Ingredients Ltd | Composition for treatment and/or nutrition of poultry |
| CN109832608A (en) * | 2017-11-28 | 2019-06-04 | 内蒙古伊利实业集团股份有限公司 | Alleviate the probiotics draft food compositions and its process for preparing buccal lozenge of throat discomfort |
| CN109528776A (en) * | 2018-06-08 | 2019-03-29 | 广东益可维健康科技有限公司 | A kind of compound probiotic lozenge of prophylactic treatment mouth disease and preparation method thereof |
| CN112957378B (en) * | 2019-12-12 | 2023-09-29 | 锦乔生物科技有限公司 | Composition for inhibiting colpitis pathogenic bacteria, vagina cleaning composition and application thereof |
| CN111471610B (en) * | 2020-03-02 | 2022-09-06 | 上海理工大学 | Lactobacillus salivarius for relieving pharyngitis |
| CN114053342A (en) * | 2020-08-04 | 2022-02-18 | 丰华生物科技股份有限公司 | Composition for promoting defecation and application thereof |
| CN115006433A (en) * | 2021-02-19 | 2022-09-06 | 丰华生物科技股份有限公司 | Anti-obesity lactic acid bacteria strain composition and application thereof |
| CN114304642A (en) * | 2021-11-25 | 2022-04-12 | 青岛康益生物科技有限公司 | A probiotic product for allergy |
| CN114053313B (en) * | 2022-01-17 | 2022-04-01 | 中科嘉亿营养医学(山东)微生态研究院有限公司 | Application of lactobacillus salivarius JYLS-372 in preparation of hangover alleviating and liver protecting product |
| CN114470010B (en) * | 2022-02-07 | 2024-02-27 | 北京华元生物技术研究院 | Novel application of bifidobacterium lactis BL-11 |
| CN114350577B (en) * | 2022-03-17 | 2022-05-27 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis BLA36 for improving constipation and culture method and application thereof |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| CN101528244A (en) * | 2006-10-02 | 2009-09-09 | 丹尼斯克有限公司 | Probiotics for use in reducing the incidence and duration of illness |
| CN101541194A (en) * | 2006-09-27 | 2009-09-23 | 利特尔卡鲁梅控股有限公司 | Probiotic oral dosage forms |
| CN101636173A (en) * | 2007-03-27 | 2010-01-27 | 宝洁公司 | Methods and kits for administering probiotics |
| CN102125105A (en) * | 2010-12-14 | 2011-07-20 | 内蒙古伊利实业集团股份有限公司 | New-prebiotics-added milk slice and preparation method thereof |
| CN102143756A (en) * | 2008-09-04 | 2011-08-03 | Om药物公司 | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| CN102159086A (en) * | 2008-09-19 | 2011-08-17 | 美赞臣营养品公司 | Probiotic infant products |
| CN102450331A (en) * | 2010-10-25 | 2012-05-16 | 王世义 | Composite active probiotics milk powder candy |
| WO2012150269A1 (en) * | 2011-05-03 | 2012-11-08 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
| CN103431134A (en) * | 2013-09-17 | 2013-12-11 | 南京通泽农业科技有限公司 | Tablet candy containing prebiotics and preparation method thereof |
| CN103547276A (en) * | 2010-11-11 | 2014-01-29 | 雀巢产品技术援助有限公司 | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
-
2014
- 2014-03-07 CN CN201510228239.9A patent/CN104957260B/en active Active
- 2014-03-07 CN CN201410083030.3A patent/CN103798392B/en active Active
- 2014-03-07 CN CN201510227769.1A patent/CN104886255B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1357038A (en) * | 1999-06-21 | 2002-07-03 | Vsl制药有限公司 | Combination of lactic acid bacteria and its use for prevention and/or treatment of infections and inflammatory conditions |
| CN1545936A (en) * | 2003-12-01 | 2004-11-17 | 上海交大昂立股份有限公司 | Edible combination containing active Lactobacillus paracasei and preparation method thereof |
| CN101031313A (en) * | 2004-11-16 | 2007-09-05 | 安尼德拉尔有限公司 | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
| CN101541194A (en) * | 2006-09-27 | 2009-09-23 | 利特尔卡鲁梅控股有限公司 | Probiotic oral dosage forms |
| CN101528244A (en) * | 2006-10-02 | 2009-09-09 | 丹尼斯克有限公司 | Probiotics for use in reducing the incidence and duration of illness |
| CN101636173A (en) * | 2007-03-27 | 2010-01-27 | 宝洁公司 | Methods and kits for administering probiotics |
| CN102143756A (en) * | 2008-09-04 | 2011-08-03 | Om药物公司 | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| CN102159086A (en) * | 2008-09-19 | 2011-08-17 | 美赞臣营养品公司 | Probiotic infant products |
| CN102450331A (en) * | 2010-10-25 | 2012-05-16 | 王世义 | Composite active probiotics milk powder candy |
| CN103547276A (en) * | 2010-11-11 | 2014-01-29 | 雀巢产品技术援助有限公司 | Non-replicating probiotic micro-organisms protect against upper respiratory tract infections |
| CN102125105A (en) * | 2010-12-14 | 2011-07-20 | 内蒙古伊利实业集团股份有限公司 | New-prebiotics-added milk slice and preparation method thereof |
| WO2012150269A1 (en) * | 2011-05-03 | 2012-11-08 | Dupont Nutrition Biosciences Aps | Probiotic bacteria for the topical treatment of skin disorders |
| CN103431134A (en) * | 2013-09-17 | 2013-12-11 | 南京通泽农业科技有限公司 | Tablet candy containing prebiotics and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103798392B (en) | 2015-12-30 |
| CN104957260A (en) | 2015-10-07 |
| CN103798392A (en) | 2014-05-21 |
| CN104886255B (en) | 2018-11-27 |
| CN104886255A (en) | 2015-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104957260B (en) | Have effects that alleviate the probiotic food composition and food of bottleneck throat inflammation | |
| CN105962086B (en) | Composition and application thereof in preparing health-care product for alleviating stomach discomfort | |
| CN105685342A (en) | Probiotic buccal tablet and preparation method thereof | |
| CN110051003A (en) | A kind of compound probiotic composition and its application | |
| JP5224606B2 (en) | Probiotic oral dosage form | |
| CN106605919A (en) | Composition used for removing food retention and relaxing bowels of children, as well as preparation method thereof | |
| CN111972670A (en) | Composition for relaxing bowel, solid beverage and application | |
| CN101636173A (en) | Methods and kits for administering probiotics | |
| CN109528776A (en) | A kind of compound probiotic lozenge of prophylactic treatment mouth disease and preparation method thereof | |
| CN104382955B (en) | A kind of composition, purposes and health products | |
| CN106722206A (en) | A kind of composition for alleviating alimentary canal malaise symptoms and/or emotional stress and products thereof | |
| KR101396458B1 (en) | A food or drink composition comprising fermented eastern prickly pear | |
| CN114831286B (en) | Composition with constipation relieving function and preparation method thereof | |
| WO2016128414A1 (en) | Probiotic strains for urinary tract infections | |
| CN109620930B (en) | Fructus amomi composition preparation and application thereof | |
| KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
| JP2017190298A (en) | Composition for producing hydrogen in body and supplement thereof | |
| CN103892028B (en) | Chewing gum capable of resisting oral helicobacter pylori, and preparation method thereof | |
| CN109832608A (en) | Alleviate the probiotics draft food compositions and its process for preparing buccal lozenge of throat discomfort | |
| WO2014134830A1 (en) | Edible composition, food product comprising same, and preparation method for the food product | |
| CN104256003B (en) | Chinese medicine composition of a kind of fiery invigorating the spleen of dispelling and preparation method thereof | |
| CN113769029A (en) | Medicinal and edible herbal composition for improving intestinal absorption and immune function | |
| CN113662192A (en) | Anti-helicobacter pylori instant lactic acid bacteria agent and preparation method and application thereof | |
| CN112137112A (en) | Composite food for dispelling effects of alcohol and protecting liver and preparation method thereof | |
| CN110538218A (en) | Composition for treating mastitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |